Osimertinib mesylate Drug Asset Due Diligence Report 2026

This Osimertinib mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

377

Registered trials

652

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Osimertinib mesylate can convert its Small molecule drug profile and EGFR L858R x EGFR T790M x EGFR-Ex19del biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Osimertinib mesylate (query alias: osimertinib)
Modality / target	Small molecule drug; EGFR L858R x EGFR T790M x EGFR-Ex19del; EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Highest global status	Approved
Originator	AstraZeneca Pharmaceuticals Co. Ltd.
Active developers	AstraZeneca Investment (China) Co. Ltd., AstraZeneca PLC, AstraZeneca AB

The MCP disease footprint includes Non-Small Cell Lung Cancer, EGFR positive non-small cell lung cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07680790	Phase 3	Not yet recruiting	850	Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
NCT07640789	Phase 3	Not yet recruiting	418	Progression-free survival (PFS)
NCT07669779	Phase 2	Recruiting	348	Number of participants with dose limiting toxicities (DLTs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study

Phase 3; n=216; evaluation: Positive. Reported fields: AE(led to discontinuation) = 5.0 % ; AE(led to discontinuation) = 13.0 %

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

Phase 2; n=69; evaluation: Positive. Reported fields: ORR = 36.0 % ( 25 - 49); ORR = 43.0 % ( 32 - 55)

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Phase 3; n=153; evaluation: Positive. Reported fields: Risk of confirmed deterioration(appetite loss): HR = 1.0(95.0% CI, 0.63 - 1.58); Risk of confirmed deterioration(appetite loss): HR = 1.0(95.0% CI, 0.63 - 1.58)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Osimertinib mesylate addresses Non-Small Cell Lung Cancer, EGFR positive non-small cell lung cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-04-25	广东银珠医药科技有限公司宣布与阿斯利康投资（中国）有限公司签署临床研究合作协议	Discovery	Financial terms not disclosed
2024-04-09	勤浩医药与阿斯利康达成合作，评估GH21联合奥希替尼治疗非小细胞肺癌患者的临床疗效	Approved	Financial terms not disclosed
2023-01-24	Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical formulation comprising osimertinib or pharmaceutically acceptable salts thereof”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of osimertinib”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition for treating osimertinib drug-resistant non-small cell lung cancer and application thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO